Seeking Alpha
10 May 2026, 10:10 UTC · 19w ago
Verdict
Headline takes no side. We score KRYS +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Krystal Biotech's oncology flagship KB707 is now considered the primary asset over VYJUVEK, driving the bull case.
So whatElevating an early-to-mid stage oncology asset to the primary value driver significantly re-rates the company's growth trajectory and total addressable market potential for investors.
More positive than 99% of claims this week
Pipeline catalysts and VYJUVEK's international rollout could drive Krystal Biotech's annual net income to $1.8–$2.9B, implying a forward PE as low as 2.9–4.6.
So whatAn exceptionally low forward PE based on massive projected net income growth signals substantial undervaluation, which would aggressively move the stock if the market prices it in.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 99% of claims this week
Krystal Biotech holds a $1B cash position that fully supports R&D without dilution risk.
More positive than 97% of claims this week
VYJUVEK generates strong cash flow with 95% gross margins since FDA approval.
More positive than 86% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The analyst rates the stock as a Buy, citing strong cash flow from VYJUVEK, a robust pipeline, and a significant cash position.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
3h ago
+11.8%
Price agrees with the score
$341.75 vs $305.71 close before publication (May 8) · not market-adjusted
KRYS chart →
